You are here:
Home / Archives for WuXi PharmaTech
China is finally feeling bullish about the stock markets once again. Just last September, Chinese regulatory authorities suspended all new IPOs following a 60% plunge in the stock market. Now the ten-month blackout is coming to an end, signaling a potentially major shift in investor sentiment. Initial public offerings are in the works for Shanghai, Hong Kong and New York.
Posted by Jim Trippon on Tuesday, June 23, 2009 at 11:12 am
Filed under china economic growth, China ISPs, china stock, china stock market, china stocks, china's economic growth, chinese economy, Medical · Tagged barack obama, China Economy, China Life, China Markets, china mobile, China Petroleum & Chemical Corp. (SNP), china stock, china stock digest, china stock investment, china stock market, china stocks, china's economic growth, china's economic stimulus package, Chinas Premier Wen Jiabao, chinese economy, chinese stock, chinese stock exchange, chinese stock market, DJIA, Far EasTone, g20, g20 meeting, global economic crisis, invest in china, Investment China, Liang Zhipeng, MSCI Hong Kong Index Fund, NASDAQ, New York stock exchange, NYSE, Powershares Golden Dragon, Shanghai Composite Index (SCI), shanghai stock exchange, Shenzhen Development Bank, Taiwan’s Financial Supervisory Commission, Thomson Reuters, USX China Index (PGJ), value of the american dollar, worldwide recession, WuXi PharmaTech, wx
// Traveling, Travelling and more Travelling: As many of you know, I was in Las Vegas last week speaking at The Money Show. I met a lot of great people. Many of you singed up for a free report China’s Top 2 Gaming Stocks, and I hope that you find that report a great addition [...]
Posted by Jim Trippon on Wednesday, May 20, 2009 at 12:05 am
Filed under china economic growth, china energy, china stock, china stock market, china stocks, china's economic growth, chinese economy, Services · Tagged China Economy, China Markets, china stock, china stock market, chinese economy, chinese stock exchange, Investment China, Thomson Reuters, WuXi PharmaTech, wx
